PPD Stock

PPD EV/EBIT

Delisted·Dec 9, 2021

The EV/EBIT (Enterprise Value to EBIT) of PPD (PPD) as of Jul 21, 2026 is 32.61. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 39.70 — a change of -17.84% (lower).

EV/EBIT

32.61

YoY

-17.84%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of PPD is 2026 32.61 . EV/EBIT (Enterprise Value to EBIT) of PPD was 2025 39.70 . It decreases by -17.84% lower compared to the previous year.

The PPD EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
23.29 base
Jan 1, 2021 (e)
0.00 base
Jan 1, 2022 (e)
0.00 base
Jan 1, 2023 (e)
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
YEARPRICE-TO-EBIT
2025 est -
2024 est -
2023 est -
2022 est -
2021 est -
2020 23.29
2019 -
2018 -
2017 -
2016 -
Access this data via the Eulerpool API

PPD Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides PPD's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates PPD's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots PPD's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if PPD grows earnings faster than its peers.

PPD Stock analysis

What does PPD do? PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs. PPD is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PPD stock

EV/EBIT (Enterprise Value to EBIT) of PPD is 32.61 in 2026.

Access this data via the Eulerpool API

Valuation — PPD

All Key Metrics — PPD